Patients with established cardiovascular disease may benefit from specific GLP-1 therapies (semaglutide, dulaglutide, or liraglutide) that have demonstrated cardiovascular risk reduction in clinical trials, though these benefits are observed during active treatment
BMJ, 335(7631), 1194-1199
Brighten Essentials use code POD15 for 15% off Lumebox Support our sponsors and help keep this show free and packed with amazing guests
Dead skin cells damage the skin, causing those uneven skin tone and skin blotches
Strategic Partnerships Power Wisps Holistic Care Model Wisp is actively building an interconnected care ecosystem through strategic partnerships: With Daye, it launched a CLIA-validated vaginal microbiome screen using diagnostic tampons for BV, yeast, and fertility insights